Belite Bio, Inc
BLTE
Rangering i aksjer
#2988
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aksjekurs
$153.04
Markedsverdi
$6.16B
Endring (1 dag)
3.87%
Endring (1 år)
69.35%
Land
US
Handel Belite Bio, Inc (BLTE)
Kategori
Healthcare
Antall utestående aksjer for Belite Bio, Inc (BLTE)
Antall utestående aksjer per June 2026: 40.18M
Ifølge Belite Bio, Inc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 40.18M. Ved slutten av December 2023 hadde selskapet 26.59M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Belite Bio, Inc (BLTE) fra 2020 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 40.18M | 31.58% |
| 2024 | 30.54M | 14.84% |
| 2023 | 26.59M | 33.12% |
| 2022 | 19.98M | -17.09% |
| 2021 | 24.10M | 161.73% |
| 2020 | 9.21M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 531.87% |
US
|
|
| 396.00M | 885.51% |
US
|
|
| 478.91M | 1,091.85% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 54.76% |
NL
|
